<DOC>
	<DOCNO>NCT01598285</DOCNO>
	<brief_summary>GEI-BEV-2011-01 Observational multicenter study . The study , involve 200 ( 100 non-responders 100 best responder ) metastatic breast cancer patient , search specific genetic variant ( SNPs ) miRNA signature associate bevacizumab response . Only patient suffer metastatic ( disseminated time diagnosis ) breast cancer , treat bevacizumab , include . 1 . -To identify genetic variant bevacizumab response predictor metastatic breast cancer 2 . To identify miRNA signature whole blood bevacizumab response predictor metastatic breast cancer patient . The main endpoint progression-free survival ( PFS ) The duration study approximately 18 month</brief_summary>
	<brief_title>A Combined GWAS miRNA Identification Bevacizumab Response Predictors Metastatic Breast Cancer</brief_title>
	<detailed_description>In certain solid neoplasia , antiangiogenic therapy improve response rate time progression . However , treatment antiangiogenic drug improve patientÂ´s overall survival , addition quite toxic expensive . It therefore critical identify reliable predictive factor drug efficacy potential toxicity . Pharmacogenomics pharmacogenetics emerge important tool optimization different therapeutic strategy cancer . Thus , gene expression profile genome-wide association study ( GWAS ) offer promise effectively tailor individual cancer treatment identify new biomarkers clinical efficacy . They likely represent real progress understand cancer complex process improvement patient management treatment . This grant proposal aim : ) identify genetic variant ( SNPs ) responsible different bevacizumab treatment response observe metastatic breast cancer patient ii ) determine specific blood microRNA ( miRNA ) signatures associate bevacizumab response The reference endpoint patient selection progression free survival ( PFS ) . To increase statistical significance study , patient categorize two group : non-responders ( PFS &lt; 12 week ) best responder ( PFS &gt; 52 week ) . Blood sample draw prospectively select patient , process obtain purified total DNA RNA , finally , analyze next-gen GWAS miRNA profiling , respectively . DNA sample hybridize ultrahigh density Omni microarrays , contain 2.5 million genetic variant RNA sample hybridize Affymetrix microarrays contain up-to-date collection human miRNA sequence ( miRBase v15 , 1105 human miRNA probe ) . Standard computational analysis set microarray data perform result correlate main endpoint study ( PFS ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient breast cancer , disseminate stage patient treat bevacizumab combination weekly paclitaxel first line chemotherapy progress alive patient authorize extraction analysis biological sample . patient second neoplasia decease patient patient agree participate study HER2 positive patient patient CNS metastasis first treat bevacizumab combination paclitaxel patient localregional recurrence patient status NED ( resect metastasis )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Genome-Wide</keyword>
	<keyword>GWAS</keyword>
	<keyword>microRNA</keyword>
	<keyword>miRNA</keyword>
	<keyword>Bevacizumab Response Predictors</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>